In late November 2018, Hamilton Health Sciences discovered an issue with the equipment used to deliver brachytherapy (BT) to patients with cervical cancer. The only patients who may have been affected by this issue are those who received this specific kind of therapy – BT – for cervical cancer in 2017 and 2018. Physicians, nurses and other members of our team have met with the
December 27, 2018 Health Canada is pleased to announce the release of the document Drug and Medical Device Databases. This document provides a comprehensive list of Health Canada’s drug and medical device databases and includes an overview of the information available in each database. The guidelines are designed to facilitate access to these databases and to inform stakeholders on what information is available. Questions or
This consultation opened on December 20, 2018. It will close on February 20, 2019. Health Canada is seeking feedback on draft regulations to minimize the public health and public safety risks posed by: edible cannabis cannabis extracts cannabis topicals These cannabis products will be permitted for legal sale under the Cannabis Act no later than October 17, 2019. The proposed regulations and Regulatory Impact Analysis Statement (RIAS) are published
From Innovative Medicines Canada: “Innovative Medicines Canada (IMC) is pleased to introduce a dynamic new Ethics and Integrity Education online tool to help its stakeholders understand the Code of Ethical Practices that guides the innovative pharmaceutical industry. With short videos, interactive features, and Q&A segments, we hope this new tool will allow you to discover IMC’s Code of Ethical Practices and its importance in your day-to-day interactions.
NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom Only test recommended based on its ability to predict chemotherapy benefit Recommendation expanded to include patients with micrometastatic disease REDWOOD CITY, Calif. – December 19, 2018 – Genomic Health, Inc. (NASDAQ: GHDX) today announced that the National Institute for Health and Care Excellence (NICE) in the
The Canadian Cancer Survivor Network currently has two feedback opportunities for prostate cancer patients and caregivers. Please read below for more information. If you qualify to take these surveys, we would appreciate you taking a few minutes to do so. If you have any questions, please contact Allison at email@example.com. Prostate Cancer Patient/Survivor/Caregiver Questionnaire All patients, survivors and caregivers who have faced or are facing